Hancock, Robert E.W.
Haney, Evan F.
Gill, Erin E.
Article History
First Online: 18 April 2016
Change Date: 28 April 2016
Change Type: Erratum
Change Details: In the original version of this article, the first subheading of Table 1 was incorrect. It should read Cathelicidin LL-37. This has now been corrected online and for the print version. We apologize for this error.
Competing interests
: R.E.W.H. is developing innate defence regulator (IDR) peptides as therapeutics and vaccine adjuvants, and has filed several patents in this area, all of which are assigned to his employer, the University of British Columbia. Two of his IDR peptides have been licensed to Elanco Animal Health Inc., for use in treatment of animals and as vaccine adjuvants, and one has been licensed to the Pan-provincial Vaccine Enterprise, for development as a component of vaccine adjuvant formulations. E.F.H. is a co-inventor on one of these patents. Recently, R.E.W.H. formed a new virtual company, ABT Innovations Inc., to promote commercialization of the University of British Columbia peptide patents. E.E.G. declares no competing interests.